ArticleOncology and therapy2026
Patient and Physician Perspectives on Prostate Cancer Data Presented at ASCO 2025.
Article in Oncology and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this plain language podcast, highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting 2025 are discussed. These insights come from the perspective of an expert patient and physician, both of whom have experience and expertise in the field of prostate cancer. This podcast is intended to broaden the reach of complex data and insights from ASCO 2025 to a broader audience, including non-specialists, helping enable better informed treatment decisions between patients and healthcare professionals. The authors begin with a brief summary of the current diagnosis and treatment landscape for patients with prostate cancer, before discussing three topics: personalized therapy for hormone-sensitive prostate cancer; new therapeutics for hormone-resistant prostate cancer; and patient quality of life and supportive care. For hormone-sensitive prostate cancer, biomarker-driven strategies based on genetic and molecular changes in tumor biology and imaging are emerging to help identify which patients may benefit from more targeted treatments. These personalized strategies provide hope to initiate treatment earlier, ultimately preventing disease progression to hormone resistance. For patients who have progressed to difficult-to-treat hormone-resistant prostate cancer, early clinical trials show promise. Novel approaches including radioligands, antibody-drug conjugates, bispecific T cell engagers, and therapy combinations are expanding future treatment options. Finally, mental health screening, educational tools to improve patients' awareness of their disease, and remote health monitoring may help improve the quality of life of patients and their families/caregivers, signposting them to appropriate supportive care. Data presented at ASCO 2025 highlights a shift in the treatment and management of prostate cancer towards a more personalized approach and further amplifies the need to consider individual patient populations. A glossary of abbreviations and terms used in this podcast is provided in the electronic supplementary material. Podcast Audio (MP4 175328 KB).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.